Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a clinical-stage biopharmaceutical company developing anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The CNSP news feed highlights the company’s announcements about its clinical programs, corporate developments, and interactions with the scientific and investment communities.
A central theme in CNS Pharmaceuticals’ news is the progress of its lead drug candidate, TPI 287. The company issues updates on clinical data, including Phase 1 results in glioblastoma patients treated with TPI 287 in combination with bevacizumab, and discusses the potential of TPI 287 to cross the blood-brain barrier and treat CNS tumors. Releases also describe the breadth of indications in which TPI 287 has been studied, from recurrent glioblastoma and pediatric neuroblastoma to metastatic melanoma and breast cancer metastatic to the brain.
News items also cover scientific visibility, such as acceptance of abstracts for poster presentation at the Society of Neuro-Oncology Annual Meeting. These abstracts, as described by the company, address topics like Berubicin in glioblastoma and pediatric diffuse midline glioma, as well as future evaluation of TPI 287 in CNS diseases. In addition, CNS Pharmaceuticals reports participation in investor conferences and virtual events, where management discusses its development strategy and corporate outlook.
Corporate and governance updates appear in the news as well, including announcements of a 1-for-12 reverse stock split and leadership changes, such as the planned transition of the chief executive officer role to Rami Levin. For investors and observers following CNSP, this news page provides a centralized view of the company’s disclosed milestones in neuro-oncology drug development, capital structure decisions, and executive leadership.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. CEO John Climaco presented at the event, sharing insights about his leadership journey and passion for the company's development programs.
The presentation is now available for viewing on virtualinvestorco.com and the Events page in the Investors section of cnspharma.com.
CNS Pharmaceuticals (NASDAQ:CNSP) has announced a 1-for-12 reverse stock split of its common stock, effective July 22, 2025. The biopharmaceutical company's stock will continue trading on the Nasdaq Capital Market under the same symbol "CNSP" but with a new CUSIP number: 18978H508.
Under this reverse split, every 12 shares will be automatically combined into one share, with proportional adjustments made to outstanding warrants and equity-based awards. The company's authorized shares will be reduced to 25 million, while maintaining a par value of $0.001 per share. Stockholders entitled to fractional shares will receive cash payments instead.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, announced CEO John Climaco's participation in a Virtual Investor CEO Connect segment. During the presentation, Climaco discussed the company's lead program TPI 287 and shared insights from the Longwood Healthcare Leaders Spring 2025 Meeting in Cambridge, MA.
CNS Pharmaceuticals (NASDAQ:CNSP) has released a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital. The segment focuses on Glioblastoma Multiforme (GBM) treatment landscape and the company's lead product candidate, TPI 287.
Dr. Dunbar, who specializes in brain and spine tumor patient care, discusses the potential of TPI 287 as a treatment for GBM and its possible applications for metastatic tumors. The virtual segment is now available for viewing online.
CNS Pharmaceuticals (NASDAQ:CNSP) has announced the pricing of a $5 million public offering with a single healthcare-focused institutional investor. The offering includes 3,952,570 shares of common stock priced at $1.265 per share. Additionally, the company will issue Series F Warrants to purchase up to 3,952,570 shares with an exercise price of $1.14 per share, exercisable immediately and expiring in five years.
The offering is expected to close around May 14, 2025. A.G.P./Alliance Global Partners is serving as the sole placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The offering is made pursuant to an effective registration statement on Form S-1.
CNS Pharmaceuticals (NASDAQ:CNSP) has successfully acquired Orphan Drug Designation for TPI 287, a novel abeotaxane drug, from Cortice Biosciences. The FDA previously granted these designations for treating gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.
TPI 287 works similarly to other taxanes by stabilizing microtubules and inhibiting cell division. Unlike most taxanes, clinical data suggests it can cross the blood-brain barrier. In a Phase 1 trial combining TPI 287 with bevacizumab for glioblastoma treatment, 3 Complete Responses and 9 Partial Responses were observed among 23 evaluable patients.
The company plans to begin Phase 2 study enrollment by year-end 2025. The Orphan Drug Designation provides benefits including tax credits, FDA fee exemptions, and potential 7-year market exclusivity post-approval.
CNS Pharmaceuticals (NASDAQ:CNSP) reported its full year 2024 financial results, highlighting a net loss reduction to $14.9 million from $18.9 million in 2023. The company's primary Berubicin trial for glioblastoma multiforme (GBM) did not meet its primary endpoint of statistical superiority in overall survival compared to Lomustine.
Research and development expenses decreased to $9.3 million from $14.1 million, while general and administrative expenses increased to $5.6 million from $4.8 million. The company holds approximately $6.5 million in cash and raised an additional $9.9 million through stock sales, providing operational funding into Q1 2026.
Moving forward, CNSP is pivoting to develop TPI 287, a novel abeotaxane licensed from Cortice Biosciences in July 2024. TPI 287 has shown promising clinical efficacy in GBM treatments and has received Orphan Drug Designation, with plans to engage FDA for potential registration study design in 2025.
CNS Pharmaceuticals (NASDAQ:CNSP) has announced the primary analysis of its clinical trial for Berubicin, an anthracycline treatment for recurrent Glioblastoma Multiforme (GBM). The study compared Berubicin to Lomustine, a standard GBM treatment.
Key findings show that while Berubicin did not demonstrate statistically significant superiority in overall survival (the primary endpoint), it showed comparable clinical outcomes to Lomustine across multiple endpoints. Notably, Berubicin displayed no cardiotoxicity, a common limitation with other anthracyclines, and maintained a favorable safety profile.
The drug is significant as the first anthracycline proven to extensively cross the blood-brain barrier. The company is continuing analysis of outcomes, including advanced imaging review and clinical endpoints. Additionally, CNS Pharmaceuticals is developing TPI 287, a novel taxane with published clinical efficacy data in GBM treatment.